1 most recent filing and news item mentioning MRVI. Updated every 60 seconds.
EarningsAug 6, 2026Positive
Maravai LifeSciences reported $51.4 million in second quarter 2026 revenue and raised its full-year Adjusted EBITDA guidance, citing growth in its TriLink and Cygnus segments.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.